Detalhe da pesquisa
1.
Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Int J Cancer
; 133(9): 2089-101, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23629727
2.
The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells.
Cancer Res
; 67(14): 6956-64, 2007 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17638907
3.
Oncogene-induced senescence and its evasion in a mouse model of thyroid neoplasia.
Mol Cell Endocrinol
; 460: 24-35, 2018 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28652169
4.
ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.
Cancer Res
; 62(24): 7284-90, 2002 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-12499271
5.
The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes.
Cancer Res
; 62(4): 1077-82, 2002 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-11861385
6.
Regulation of p27Kip1 protein levels contributes to mitogenic effects of the RET/PTC kinase in thyroid carcinoma cells.
Cancer Res
; 64(11): 3823-9, 2004 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-15172989
7.
H4(D10S170), a gene frequently rearranged with RET in papillary thyroid carcinomas: functional characterization.
Oncogene
; 23(1): 109-21, 2004 Jan 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-14712216
8.
Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models.
Clin Cancer Res
; 21(18): 4153-64, 2015 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26019172
9.
Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.
Clin Cancer Res
; 21(13): 2975-83, 2015 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25838391
10.
SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer.
Clin Cancer Res
; 21(20): 4686-97, 2015 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26124204
11.
AXL is an oncotarget in human colorectal cancer.
Oncotarget
; 6(27): 23281-96, 2015 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25966280
12.
ONYX-015, an E1B gene-defective adenovirus, induces cell death in human anaplastic thyroid carcinoma cell lines.
J Clin Endocrinol Metab
; 87(6): 2525-31, 2002 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-12050209
13.
Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2).
J Clin Endocrinol Metab
; 88(4): 1897-902, 2003 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-12679489
14.
Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition.
Clin Cancer Res
; 20(14): 3775-86, 2014 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24812410
15.
Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines.
Clin Cancer Res
; 19(13): 3508-19, 2013 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23695170
16.
Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells.
Clin Cancer Res
; 19(24): 6751-65, 2013 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24122793
17.
Novel candidate genes of thyroid tumourigenesis identified in Trk-T1 transgenic mice.
Endocr Relat Cancer
; 19(3): 409-21, 2012 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-22454401
18.
The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells.
Endocr Relat Cancer
; 18(1): 1-11, 2011 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-20943719
19.
Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.
Clin Cancer Res
; 16(20): 4990-5001, 2010 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20810384